NDAINJECTIONINJECTABLE
Approved
Oct 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
THALLOUS CHLORIDE TL 201 (thallous chloride, tl 201) by Curium Pharma is 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. First approved in 1979.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Thallous Chloride Tl 201 is a radioactive diagnostic agent administered via injection that accumulates in viable myocardium analogous to potassium, enabling visualization of regional perfusion and detection of myocardial infarction and ischemia. It is used in cardiac imaging to identify areas of reduced blood flow and dead tissue as "cold" spots on imaging scans. The drug's mechanism relies on its preferential uptake in healthy heart muscle, making it a cornerstone diagnostic tool in nuclear cardiology.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests a contracting team focused on maintaining market share in a mature diagnostic imaging niche.
Mechanism of Action
201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Thallous Chloride Tl 201 represents a specialty diagnostic career opportunity in a mature product with limited growth potential and minimal linked job openings currently available. This role suits professionals seeking stability in a niche cardiology space or those transitioning toward healthcare reimbursement and market access functions.
Worked on THALLOUS CHLORIDE TL 201 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.